retatrutide clinical trials safety efficacy and of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Retatrutide for the treatment of

Gallbladder, Pancreatitis and Other Less Common Events Beyond gastrointestinal symptoms, several less frequent adverse events appear in the trial data at rates worth understanding neither dismissed nor overstated

Preclinical studies with GLP-1 agonists have raised questions about thyroid C-cell tumours in rodents, though this has not been confirmed in humans

The scale was stalling because I was simultaneously losing fat and holding more water temporarily

Without an official SmPC, no confirmed refrigerated shelf-life or in-use storage period can be stated

If you havent lost at least 5% body weight by week 12, discuss dose escalation with your physician

Semaglutide is the first of several highly effective and safe anti-obesity medications in the pipeline, and more research will include teenagers. While the medication may be the best option for some teenagers, Batash said providers should take extra care to evaluate young patients